Your Location：
Home >
Browse articles >
Effect of Yiqi Tongmai Formula in Intervening in Liver Inflammation and Lipidosis in ApoE-∕- Mice Based on NF-κB/NLRP3 Signaling Pathway
Updated：2024-07-04
Previous|Next

    • Effect of Yiqi Tongmai Formula in Intervening in Liver Inflammation and Lipidosis in ApoE-∕- Mice Based on NF-κB/NLRP3 Signaling Pathway

    • CHEN Yuhan , REN Quanna , WANG Kun , SU Tingting , YANG Yanhua , MA Ming , ZHANG Yu , ZHAO Xu
    • Chinese Journal of Experimental Traditional Medical Formulae Vol. 30, Issue 15, Pages: 64-72(2024)

    • DOI： 10.13422/j.cnki.syfjx.20240803     

      CLC：

    Scan QR Code

  •  
  •  

  • AI Introduction

  • Full Text(HTML)

  • Figs( 7 ) Tabs( 6 )

  • References

  • Publication Info

  • Metrics

187

Views

153

Downloads

1

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Iron Homeostasis Imbalance Promotes Atherosclerosis and Therapeutic Mechanisms of Traditional Chinese Medicine
Mechanism of Huoxin Pills in Stabilizing Atherosclerotic Vulnerable Plaque Based on Network Pharmacology and Metabolomics
Differentiation and Treatment of Vulnerable Atherosclerotic Plaque Based on "Collateral Disease" Theory
Effect and Molecular Mechanisms of Danlou Tablet on Hepatic Lipid Deposition in ApoE-/- Atherosclerotic Mice Through Regulation of SIRT6/CREB/Nor1 Signaling Pathway-mediated Autophagy
Regulatory Pathways of Cell Apoptosis in Diabetic Kidney Disease and Intervention by Traditional Chinese Medicine： A Review

Related Author

WANG Maohong
XIONG Jianhua
ZHANG Hao
YAN Xiaohong
WAN Qiang
XIANG Jiao
LUO Jieying
LIAO Daiyuan

Related Institution

Jiangxi University of Chinese Medicine
The Affiliated Hospital of Jiangxi University of Chinese Medicine
School of Chinese Materia Medica，Guangzhou University of Chinese Medicine
Baiyunshan Pharmaceutical General Factory， Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd.
Guangzhou Caizhilin Pharmaceutical Co. Ltd.